|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 2 | Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: A systematic review and meta analysis显示文摘AIM: To detect pancreatic neuroendocrine tumors (PNETs) has been varied. This study is undertaken to evaluate the accuracy of endoscopic ultrasound (EUS) in detecting PNETs.METHODS: Only EUS studies confirmed by surgery or appropriate follow-up were selected. Articles were searched in Medline, Ovid journals, Medline nonindexed citations, and Cochrane Central Register of Controlled Trials and Database of Systematic Reviews. Pooling was conducted by both fixed and random effects model). RESULTS: Initial search identified 2610 reference articles, of these 140 relevant articles were selected and reviewed. Data was extracted from 13 studies (n = 456) which met the inclusion criteria. Pooled sensitivity of EUS in detecting a PNETs was 87.2% (95%CI: 82.2-91.2). EUS had a pooled specificity of 98.0% (95%CI: 94.3-99.6). The positive likelihood ratio of EUS was 11.1 (95%CI: 5.34-22.8) and negative likelihood ratio was 0.17 (95%CI: 0.13-0.24). The diagnostic odds ratio, the odds of having anatomic PNETs in positive as compared to negative EUS studies was 94.7 (95%CI: 37.9-236.1). Begg-Mazumdar bias indicator for publication bias gave a Kendall's tau value of 0.31 (P = 0.16), indication no publication bias. The P for χ2 heterogeneity for all the pooled accuracy estimates was > 0.10. CONCLUSION: EUS has excellent sensitivity and specificity to detect PNETs. EUS should be strongly considered for evaluation of PNETs. | Srinivas R Puli Nikhil Kalva Matthew L Bechtold Smitha R Pamulaparthy Micheal D Cashman Norman C Estes Richard H Pearl Fritz-Henry Volmar Sonu Dillon Michael F Shekleton David Forcione | 2013 | World Journal of Gastroenterology2013，19，23： | 14 |
| 3 | Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice显示文摘BACKGROUND Type 1 diabetes(T1D) is associated with major chronic microvascular complications which contribute significantly to diabetes associated morbidity.The protein primarily responsible for glucose reabsorption in the kidney is sodium glucose co-transporter 2(SGLT2). Presently, SGLT2 inhibitors are widely used in diabetic patients to improve blood glucose levels and prevent cardiovascular and renal complications. Given the broad therapeutic application of SGLT2 inhibitors, we hypothesised that SGLT2 inhibition may exert its protective effects via alterations of the gut microbiome and tested this in a type 1 diabetic mouse model of diabetic retinopathy.AIM To determine whether the treatment with two independent SGLT2 inhibitors affects gut health in a type 1 diabetic mouse model.METHODS The SGLT2 inhibitors empagliflozin or dapagliflozin(25 mg/kg/d) or vehicle dimethylsulfoxide(DMSO) were administered to C57 BL/6 J, Akita, Kimba and Akimba mice at 10 wk of age for 8 wk via their drinking water. Serum samples were collected and the concentration of succinate and the short chain fatty acid(SCFA) butyric acid was measured using gas chromatography-mass spectrometry. Enzyme-linked immunosorbent assay(ELISA) was performed to determine the concentration of insulin and leptin. Furthermore, the norepinephrine content in kidney tissue was determined using ELISA. Pancreatic tissue was collected and stained with haematoxylin and eosin and analysed using brightfield microscopy.RESULTS Due to the presence of the Akita allele, both Akita and Akimba mice showed a reduction in insulin production compared to C57 BL/6 J and Kimba mice.Furthermore, Akita mice also showed the presence of apoptotic bodies within the pancreatic islets. The acinar cells of Akita and Akimba mice showed swelling which is indicative of acute injury or pancreatitis. After 8 wk of SGLT2 inhibition with dapagliflozin, the intermediate metabolite of gut metabolism known as succinate was significantly reduced in Akimba mice when compared to DMSO treated mice. In addition, empagliflozin resulted in suppression of succinate levels in Akimba mice. The beneficial SCFA known as butyric acid was significantly increased in Akita mice after treatment with dapagliflozin when compared to vehicle treated mice. The norepinephrine content in the kidney was significantly reduced with both dapagliflozin and empagliflozin therapy in Akita mice and was significantly reduced in Akimba mice treated with empagliflozin.In non-diabetic C57 BL/6 J and Kimba mice, serum leptin levels were significantly reduced after dapagliflozin therapy.CONCLUSION The inhibition of SGLT2 reduces the intermediate metabolite succinate, increases SCFA butyric acid levels and reduces norepinephrine content in mouse models of T1 D. Collectively, these improvements may represent an important mechanism underlying the potential benefits of SGLT2 inhibition in T1 D and its complications. | Lakshini Y Herat Natalie C Ward Aaron L Magno Elizabeth P Rakoczy Marcio G Kiuchi Markus P Schlaich Vance B Matthews | 2020 | World Journal of Gastroenterology2020，26，23： | 3 |
| 4 | Naming and outline of Dothideomycetes-2014 including proposals for the protection or suppression of generic names显示文摘Article 59.1,of the International Code of Nomenclature for Algae,Fungi,and Plants(ICN;Melbourne Code),which addresses the nomenclature of pleomorphic fungi,became effective from 30 July 2011.Since that date,each fungal species can have one nomenclaturally correct name in a particular classification.All other previously used names for this species will be considered as synonyms.The older generic epithet takes priority over the younger name.Any widely used younger names proposed for use,must comply with Art.57.2 and their usage should be approved by the Nomenclature Committee for Fungi(NCF).In this paper,we list all genera currently accepted by us in Dothideomycetes(belonging to 23 orders and 110 families),including pleomorphic and nonpleomorphic genera.In the case of pleomorphic genera,we follow the rulings of the current ICN and propose single generic names for future usage.The taxonomic placements of 1261 genera are listed as an outline.Protected names and suppressed names for 34 pleomorphic genera are listed separately.Notes and justifications are provided for possible proposed names after the list of genera.Notes are also provided on recent advances in our understanding of asexual and sexual morph linkages in Dothideomycetes.A phylogenetic tree based on four gene analyses supported 23 orders and 75 families,while 35 families still lack molecular data. | Nalin N.Wijayawardene Pedro W.Crous Paul M.Kirk David L.Hawksworth Saranyaphat Boonmee Uwe Braun Dong-Qin Dai Melvina J.D’souza Paul Diederich Asha Dissanayake Mingkhuan Doilom Singang Hongsanan E.B.Gareth Jones Johannes Z.Groenewald Ruvishika Jayawardena James D.Lawrey Jian-Kui Liu Robert Lücking Hugo Madrid Dimuthu S.Manamgoda Lucia Muggia Matthew P.Nelsen Rungtiwa Phookamsak Satinee Suetrong Kazuaki Tanaka Kasun M.Thambugala Dhanushka N.Wanasinghe Saowanee Wikee Ying Zhang Andre Aptroot H.A.Ariyawansa Ali H.Bahkali D.Jayarama Bhat Cécile Gueidan Putarak Chomnunti G.Sybren De Hoog Kerry Knudsen Wen-Jing Li Eric H.C.McKenzie Andrew N.Miller Alan J.L.Phillips Marcin Piatek Huzefa A.Raja Roger S.Shivas Bernad Slippers Joanne E.Taylor Qing Tian Yong Wang Joyce H.C.Woudenberg Lei Cai Walter M.Jaklitsch Kevin D.Hyde | 2014 | Fungal Diversity2014，，6： | 2 |
| 5 | Categorization of Scope 3 Emissions for Streamlined Enterprise Carbon Footprinting 显示文摘 | Huang Y A Weber C L Matthews H S | 2009 | Environmental Science & Technology2009，43，22： | 1 |
| 6 | Embodied environment emissions in U S international trade: 1997-2004 显示文摘 | Weber C L Matthews H S | 2007 | Environmental Science and Technology2007，41，14： | 1 |
| 7 | Embodied environmental emissions in US international trade, 1997-2004 显示文摘 | Weber C L Matthews H S | 2007 | Environmental Science & Technology2007，41，14： | 1 |
| 8 | Mycobacteriosis in zebrafish ( Danio rerio ) research facilities 显示文摘 | Kent M L Whipps C M Matthews J L | 2004 | Comparative Biochemistry and Physiology Part C2004，138，： | 1 |
| 9 | The Importance of Carbon Footprint Estimation Boundaries 显示文摘 | Matthews H S Hendrickson C T Weber C L | 2008 | Environmental Science & Technology2008，42，16： | 1 |
| 10 | Depletion of langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin显示文摘 | MATTHEWS K LEONG C M BAXTER L | 2003 | J Virol2003，77，： | 1 |
| 11 | Embodied Environmental Emissions in US International Trade 1997 - 2004 显示文摘 | Weber C L Matthews H S | 2007 | Environmental Science and Technology2007，41，： | 1 |
| 12 | Psychological Perspectives on Pathways Linking Socioeconomic Status and Physical Heahh显示文摘 | Matthews K A Gallo L C | 2011 | Annual Review of Psychology2011，，4： | 1 |
| 13 | Blind pinning of dis-placed supracondylar fracture of the humerus in children six-teen years exerience with tong-term follow-up显示文摘 | FLYNN J C MATTHEWS J G BENOIT R L | 1974 | J Bone Joint Surg AM1974，56，2： | 1 |
| 14 | Blind pinning of displaced supracondylar facture of the humerus in children sixteen years exerience with tong-term follow-up显示文摘 | FLYNN J C MATTHEWS J G BENOIT R L | 1974 | J Bone Joint Surg AM1974，56，2： | 1 |
| 15 | Approach to bioremediation of contaminated surface soil显示文摘 | SIM J L SIM R C MATTHEWS J E | 1990 | EPA1990，60，1： | 1 |
| 16 | Alterations in the energy metabolism of an estuarine mysid (Mysidopsis bahia ) as indicators of stress from chronic pesticide exposure 显示文摘 | MCKENNEY JR C L MATTHEWS E | 1990 | Marine Environmental Research1990，30，1： | 1 |
| 17 | The importance of carbon footprint estimation boundaries 显示文摘 | Matthews H S Hendrickson C T Weber C L | 2008 | Environmental Science & Technology2008，42，16： | 1 |
| 18 | Blind pinning of displaced supracondylar fractures of the humerus in children: sixteen years experience with long-tenn follow-up 显示文摘 | Flynn J C Matthews J G Benoit R L | 1974 | J Bone Joint Surg Am1974，56，2： | 1 |
| 19 | Abrasive wear/corrosion properties and TEM analysis of Al2O3 coatings fabricated using plasma electrolysis显示文摘 | NIE X MELETIS E I JIANG J C LEYLAND A YEROKHIN A L MATTHEWS A | 2002 | Surface and Coating Technology2002，149，23： | 1 |
| 20 | Review of the pest sta- tus and control options for Thrips palmi显示文摘 | Cannon R J C Matthews L Collins A D W | 2007 | Crop Protection2007，26，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员